Author Archives: Patricia Inacio PhD

KalVista Confirms Mechanism of Action of Potential HAE Therapy KVD900

KVD900, a potential new approach for treating hereditary angioedema, prevents the breakdown of kininogen and subsequent buildup of bradykinin — the underlying cause of the disease, KalVista Pharmaceuticals announced. The company confirmed this mechanism of action using a new test that measures the amounts of high molecular weight kininogen in the plasma. The…

Investigational BCX7353 Delivered to First Patient in APeX-2 Trial

A Phase 3 trial testing BCX7353, an inhibitor of plasma kallikrein for the prevention of swelling attacks in hereditary angioedema (HAE) patients, has dosed its first participant, BioCryst Pharmaceuticals announced. The trial, APeX-2, will include roughly 100 patients with type 1 and type 2 hereditary angioedema in several centers in the…

BioCryst Starts Long-Term Trial of BCX7353’s Ability to Prevent Hereditary Angioedema Attacks

A long-term clinical trial testing BCX7353’s ability to prevent hereditary angioedema (HAE) attacks is dosing its first group of participants, BioCryst Pharmaceuticals announced. “Initiation of the APeX-S trial is an important milestone to support filing and approval of BCX7353, and furthers our core strategy of bringing a once-daily, oral prophylactic…